NCT06930352 - Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 10, 2026

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Acute Myeloid Leukemia

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow biopsy and/or aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy and/or aspiration

DRUG

Cytarabine

Given cytarabine

PROCEDURE

Echocardiography Test

Undergo ECHO

DRUG

Hydroxyurea

Given hydroxyurea

PROCEDURE

Leukapheresis

Undergo leukapheresis

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Ziftomenib

Given PO

Trial Locations (1)

Ohio State University Comprehensive Cancer Center, Columbus